Department of Global Health, Milken Institute School of Public Health, The George Washington University, Washington D.C., USA.
Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA.
Vaccine. 2023 Aug 7;41(35):5159-5181. doi: 10.1016/j.vaccine.2023.06.073. Epub 2023 Jul 11.
Existing ethics guidance and regulatory requirements emphasize the need for pregnancy-specific safety and efficacy data during the development of vaccines in health emergencies. Our objective was to conduct a systematic review of vaccine clinical trials during active epidemic periods.
We searched for Phase II and Phase III vaccine clinical trials initiated during the H1N1 influenza, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Zika, and Ebola virus disease (EVD) outbreaks from 2009 to 2019. Data were extracted from clinical trial protocols identified in the following registries: ClinicalTrials.gov, Pan African Clinical Trial Registry (PACTR), and all primary registries indicated by the World Health Organization's International Clinical Trials Registry Platform (ICTRP). Published studies from registered clinical trials were located through PubMed. Data was extracted on eligibility criteria and pregnancy outcomes. Data from this study is available in the Center for Open Science Data Repository: https://osf.io/nfk2p/?view_only=47deb3b206724af9b46c9c0c0083a267.
We identified 96 vaccine clinical trial protocols and included 84 in analysis. 5 records were excluded in screening for irrelevant abstracts, 7 were excluded in full-text assessment (1 for a therapeutic drug trial, 3 for enrolling elderly adults only, 3 for enrolling children/adolescents only). There were no eligible trials for MERS-CoV or Zika virus vaccines. Overall, 8 protocols explicitly included pregnant people; of these, 3 were completed trials with published results. Incidental pregnancies and outcomes of pregnant participants were reported in 2 studies, 10 studies reported serious adverse events related to pregnancy without mentioning total incidental pregnancies. A total of 411 recorded pregnancy outcomes were reported, with 293 from the 3 pregnancy-eligible studies with results. 71 serious adverse events pertaining to pregnancy were reported from all clinical trials with results.
Pregnant people are underrepresented in vaccine clinical trials conducted during outbreaks, resulting in underreporting of pregnancy-related outcomes and a lack of protection for pregnant people and neonates from infectious diseases.
现有的伦理指导和监管要求强调,在卫生紧急情况下开发疫苗时,需要有专门针对妊娠的安全性和有效性数据。我们的目的是对活跃传染病期间的疫苗临床试验进行系统回顾。
我们检索了 2009 年至 2019 年期间在 H1N1 流感、中东呼吸综合征冠状病毒(MERS-CoV)、寨卡和埃博拉病毒病(EVD)疫情期间启动的 II 期和 III 期疫苗临床试验。从以下注册处确定的临床试验方案中提取数据:ClinicalTrials.gov、泛非临床试验注册中心(PACTR)和世界卫生组织国际临床试验注册平台(ICTRP)指示的所有主要注册处。通过 PubMed 查找已注册临床试验的已发表研究。提取入选标准和妊娠结局的数据。本研究的数据可在开放科学数据存储库中获得:https://osf.io/nfk2p/?view_only=47deb3b206724af9b46c9c0c0083a267。
我们确定了 96 项疫苗临床试验方案,并将 84 项纳入分析。在筛选不相关的摘要时排除了 5 份记录,在全文评估时排除了 7 份记录(1 份为治疗性药物试验,3 份仅纳入老年人,3 份仅纳入儿童/青少年)。没有符合 MERS-CoV 或寨卡病毒疫苗要求的合格试验。总体而言,有 8 项方案明确纳入了孕妇;其中,3 项为已完成并有结果的试验。有 2 项研究报告了偶然妊娠和孕妇结局,10 项研究报告了与妊娠相关的严重不良事件,但未提及总偶然妊娠数。共报告了 411 例记录的妊娠结局,其中 293 例来自有结果的 3 项妊娠合格研究。共有 71 例与妊娠相关的严重不良事件来自所有有结果的临床试验。
在疫情期间进行的疫苗临床试验中,孕妇代表性不足,导致妊娠相关结局报告不足,无法为孕妇和新生儿提供传染病保护。